A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India

BackgroundThe medical management of DT comprises tyrosine kinase inhibitors (TKIs), hormonal agents, anti-inflammatory drugs with the recently approved gamma secretase inhibitor nirogacestat being the current standard of care. Real-world data on evolving treatment landscapes of DT remains scarce.Met...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Ghazal Tansir, Aparna Sharma, Bivas Biswas, Suryadev Narayan Sah, Somnath Roy, S. V. S. Deo, Sandeep Agarwala, Shah Alam Khan, Sameer Bakhshi, Deepam Pushpam
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2024-10-01
Rangatū:	Frontiers in Oncology
Ngā marau:	Desmoid tumor tyrosine kinase inhibitors oral metronomic therapy quality of life rare diseases
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1382856/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India

Ngā tūemi rite